212 related articles for article (PubMed ID: 34746851)
1. Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records.
Carry BJ; Young K; Fielden S; Kelly MA; Sturm AC; Avila JD; Martin CL; Kirchner HL; Fornwalt BK; Haggerty CM;
JACC CardioOncol; 2021 Oct; 3(4):550-561. PubMed ID: 34746851
[TBL] [Abstract][Full Text] [Related]
2. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
[TBL] [Abstract][Full Text] [Related]
3. Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers of
Kaniper S; Lynch D; Owens SM; Ibric L; Vabishchevich Y; Nyantakyi N; Chun F; Sam L; Fabrizio C; Hamad E; Gerhard GS
J Pers Med; 2024 Feb; 14(3):. PubMed ID: 38541013
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of
Lopes LR; Futema M; Akhtar MM; Lorenzini M; Pittman A; Syrris P; Elliott PM
Amyloid; 2019 Dec; 26(4):243-247. PubMed ID: 31554435
[No Abstract] [Full Text] [Related]
6. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
[TBL] [Abstract][Full Text] [Related]
7. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
8. Genomic Screening Identifies Individuals at High Risk for Hereditary Transthyretin Amyloidosis.
Soper ER; Suckiel SA; Braganza GT; Kontorovich AR; Kenny EE; Abul-Husn NS
J Pers Med; 2021 Jan; 11(1):. PubMed ID: 33467513
[TBL] [Abstract][Full Text] [Related]
9. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
[TBL] [Abstract][Full Text] [Related]
10. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
12. Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.
Agbor-Etang BB; Okafor HE; Farber-Eger EH; Wells QS
Am J Med; 2021 Feb; 134(2):e98-e100. PubMed ID: 32866461
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.
Kozlitina J; Garg S; Drazner MH; Matulevicius SA; Ayers C; Overton J; Reid J; Baras A; Rao K; Pandey A; Berry J; de Lemos JA; Grodin JL
J Card Fail; 2022 Mar; 28(3):403-414. PubMed ID: 34634447
[TBL] [Abstract][Full Text] [Related]
14. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
Parker MM; Damrauer SM; Tcheandjieu C; Erbe D; Aldinc E; Hawkins PN; Gillmore JD; Hull LE; Lynch JA; Joseph J; Ticau S; Flynn-Carroll AO; Deaton AM; Ward LD; Assimes TL; Tsao PS; Chang KM; Rader DJ; Fitzgerald K; Vaishnaw AK; Hinkle G; Nioi P
Sci Rep; 2021 Jun; 11(1):11645. PubMed ID: 34079032
[TBL] [Abstract][Full Text] [Related]
15. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
[TBL] [Abstract][Full Text] [Related]
16. Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Sinha A; Zheng Y; Nannini D; Qu Y; Hou L; Shah SJ; Yancy CW; McNally EM; Fornage M; Lima J; Lloyd-Jones DM; Rasmussen-Torvik LJ; Khan SS
JAMA Cardiol; 2020 Dec; 6(6):1-5. PubMed ID: 33355618
[TBL] [Abstract][Full Text] [Related]
17. Coexisting transthyretin and atrial natriuretic peptide amyloid on left atrium in transthyretin amyloid cardiomyopathy.
Kuyama N; Takashio S; Nakamura K; Nishigawa K; Hanatani S; Usuku H; Yamamoto E; Ueda M; Fukui T; Tsujita K
J Cardiol Cases; 2024 Jun; 29(6):261-264. PubMed ID: 38826764
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
Law S; Petrie A; Chacko L; Cohen OC; Ravichandran S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Fontana M; Gillmore JD
ESC Heart Fail; 2020 Dec; 7(6):3942-3949. PubMed ID: 32924285
[TBL] [Abstract][Full Text] [Related]
19. The Frequency of V122I Transthyretin Mutation in a Cohort of African American Individuals With Bilateral Carpal Tunnel Syndrome.
Shije JZ; Bautista MAB; Smotherman C
Front Neurol; 2022; 13():949401. PubMed ID: 35959393
[TBL] [Abstract][Full Text] [Related]
20. High Hereditary Transthyretin-Related Amyloidosis Prevalence in Crete: Genetic Heterogeneity and Distinct Phenotypes.
Tzagournissakis M; Foukarakis E; Samonakis D; Tsilimbaris M; Michaelidou K; Mathioudakis L; Marinis A; Giannakoudakis E; Spanaki C; Skoula I; Erimaki S; Amoiridis G; Koutsis G; Koukouraki S; Stylianou K; Plaitakis A; Mitsias PD; Zaganas I
Neurol Genet; 2022 Oct; 8(5):e200013. PubMed ID: 36101541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
